Drugs / Secukinumab
Secukinumab
also known as
AIN457 · Cosentyx · AIN457A · CMAB015 · Cosentyx TM · Secukinumab (AIN457) 150 mg s.c.
Monoclonal antibody targets IL17A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 24 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Filed enthesitis-related juvenile idiopathic arthritis 1 milestone | |||||
| Filed | EU (EMA) | Cosentyx | enthesitis-related juvenile idiopathic arthritis | 2021-12-23 | “Novartis has filed a regulatory submission for Cosentyx in ERA and JPsA in Europe with a decision anticipated in the coming months.” novartis.com ↗ |
| Filed juvenile ankylosing spondylitis 5 milestones | |||||
| Filed | US (FDA) | Cosentyx | juvenile ankylosing spondylitis | 2021-11-08 | “has recently filed for US and European regulatory approval for Cosentyx as a potential treatment in juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA)” novartis.com ↗ “Novartis has filed regulatory submissions for Cosentyx in ERA and JPsA in Europe and the US.” novartis.com ↗ |
| Filed | EU (EMA) | Cosentyx | juvenile ankylosing spondylitis | 2021-11-08 | “has recently filed for US and European regulatory approval for Cosentyx as a potential treatment in juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA)” novartis.com ↗ “Novartis has filed regulatory submissions for Cosentyx in ERA and JPsA in Europe and the US.” novartis.com ↗ |
| Filed | US (FDA) | Cosentyx | juvenile ankylosing spondylitis | 2020-04-28 | “Cosentyx received a positive CHMP opinion for treatment of patients with non-radiographic axSpA, the fourth indication. Also the filing was accepted in the US.” novartis.com ↗ “filings, including in the US and EU, which were completed for both indications in the second quarter of 2015.” novartis.com ↗ “Novartis has also submitted Cosentyx for review by the US Food and Drug Administration (FDA)” novartis.com ↗ |
| Filed | EU (EMA) | Cosentyx | juvenile ankylosing spondylitis | 2019-09-17 | “filings, including in the US and EU, which were completed for both indications in the second quarter of 2015.” novartis.com ↗ “Novartis has submitted to EMA for approval in nr-axSpA, which would be the fourth indication for Cosentyx” novartis.com ↗ |
| Filed | Japan (PMDA) | Cosentyx | juvenile ankylosing spondylitis | — | “Novartis has also submitted Cosentyx for review by the US Food and Drug Administration (FDA) and the Japan Pharmaceuticals and Medical Devices Agency (PMDA)” novartis.com ↗ |
| Filed polymyalgia rheumatica 3 milestones | |||||
| Filed | US (FDA) | Cosentyx | polymyalgia rheumatica | 2026-04-28 | “Regulatory submissions were completed for Cosentyx in polymyalgia rheumatica (PMR) in the US, Europe and Japan.” novartis.com ↗ “Data have been submitted for health authority review in US, EU and Japan” novartis.com ↗ |
| Filed | Japan (PMDA) | Cosentyx | polymyalgia rheumatica | 2026-04-28 | “Regulatory submissions were completed for Cosentyx in polymyalgia rheumatica (PMR) in the US, Europe and Japan.” novartis.com ↗ “Data have been submitted for health authority review in US, EU and Japan” novartis.com ↗ |
| Filed | EU (EMA) | Cosentyx | polymyalgia rheumatica | 2026-04-28 | “Regulatory submissions were completed for Cosentyx in polymyalgia rheumatica (PMR) in the US, Europe and Japan.” novartis.com ↗ “Data have been submitted for health authority review in US, EU and Japan” novartis.com ↗ |
| Filed psoriasis 1 milestone | |||||
| Filed | US (FDA) | Cosentyx | psoriasis | 2020-10-27 | “FDA has accepted a submission for Cosentyx in moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years” novartis.com ↗ “Cosentyx Submitted in the US for pediatric psoriasis indication.” novartis.com ↗ |
| Filed psoriatic arthritis 2 milestones | |||||
| Filed | EU (EMA) | Cosentyx | psoriatic arthritis | — | “filings, including in the US and EU, which were completed for both indications in the second quarter of 2015.” novartis.com ↗ |
| Filed | US (FDA) | Cosentyx | psoriatic arthritis | — | “filings, including in the US and EU, which were completed for both indications in the second quarter of 2015.” novartis.com ↗ |
| Approved Indication not stated 3 milestones | |||||
| Label expansions (10) | US (FDA) | COSENTYX | — | 2016-01-15 – 2026-03-12 | fda.gov ↗ |
| Approved | US (FDA) | COSENTYX | — | 2015-01-21 | fda.gov ↗ |
| Approved | EU (EMA) | Cosentyx | — | 2015-01-14 | europa.eu ↗ |
Trials 176 · started per year
today
EU approved 2015
US approved 2015
1
1
4
8
10
12
10
10
7
14
18
11
7
9
15
9
7
6
6
5
6
20062007200820092010201120122013201420152016201720182019202020212022202320242025202620272028
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 02 trials | ||||||
| Phase 0 | NCT04414605 | Jun 2020 → Dec 2021 | psoriasis | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 0 | NCT03099980 | Jul 2016 → Dec 2018 | hidradenitis suppurativa | Tufts Medical Center | Completed | No outcome recorded |
| Phase 110 trials · 1 met primary | ||||||
| Phase 1 | NCT07237594 | Mar 2026 → Jun 2027 expected | metastatic melanoma | Duke University | Recruiting | No outcome recorded |
| Phase 1 | NCT07254325 | Dec 2025 → Jun 2026 overdue | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Active not recruiting | No outcome recorded |
| Phase 1 | NCT06751238 | Sep 2025 → Oct 2029 expected | psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1 | NCT06130540 | Mar 2024 → Mar 2025 | polymyalgia rheumatica, temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05734482 | Feb → Jul 2023 | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | Met primary |
| Phase 1 | NCT05522517 | Aug → Nov 2022 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT04967950 | Jul 2021 → Oct 2022 | psoriatic arthritis | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| Phase 1 | NCT03342573 | Apr 2018 → Jan 2022 | adult onset pityriasis rubra pilaris | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02607774 | Dec 2015 → Dec 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01539213 | Feb 2012 → Jan 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/26 trials | ||||||
| Phase 1/2 | NCT04298320 | Mar 2020 → Feb 2022 | colorectal cancer | Yanqiao Zhang | Unknown | No outcome recorded |
| Phase 1/2 | NCT03079531 | Jun 2017 → Jan 2019 | rosacea | Anne Chang | Completed | No outcome recorded |
| Phase 1/2 | NCT02733094 | Apr 2016 → Sep 2019 | pyoderma gangrenosum | Technical University of Munich | Completed | No outcome recorded |
| Phase 1/2 | NCT00920933 | Jan → Nov 2009 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00669916 | Feb → Nov 2007 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT00669942 | Dec 2005 → Nov 2008 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 240 trials · 3 met primary · 6 missed | ||||||
| Phase 2 | NCT07477795 | Apr 2026 → Oct 2029 expected | Takayasu arteritis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT04274166 | May → Dec 2021 | pyoderma gangrenosum | Wake Forest University Health Sciences | Withdrawn | No outcome recorded |
| Phase 2 | NCT03651518 | Oct 2020 → Nov 2025 | autoimmune disease, inflammatory disease | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 2 | NCT04300296 | Jul 2020 → Nov 2021 | lichen planus | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT04403243 | May → Jul 2020 | COVID-19 | Lomonosov Moscow State University Medical Research and Educational Center | Completed | No outcome recorded |
| Phase 2 | NCT03866317 | Sep 2019 → Jun 2021 | discoid lupus erythematosus | Massachusetts General Hospital | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT03791060 | Apr 2019 → Jan 2021 | necrobiosis lipoidica | Beth Israel Deaconess Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT03765788 | Jan 2019 → Jun 2021 | temporal arteritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT03568136 | Sep 2018 → May 2020 | atopic eczema | GWT-TUD GmbH | Completed | No outcome recorded |
| Phase 2 | NCT03344640 | Dec 2017 → Aug 2019 | disease of the tendon | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT03131570 | May 2017 → Jan 2020 | psoriasis | James G. Krueger, MD, PhD | Completed | No outcome recorded |
| Phase 2 | NCT03041038 | Dec 2016 → Aug 2020 | Netherton syndrome, congenital non-bullous ichthyosiform erythroderma, epidermolytic ichthyosis, lamellar ichthyosis | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT02854163 | Oct 2016 → Sep 2019 | psoriatic arthritis | University of Liverpool | Completed | No outcome recorded |
| Phase 2 | NCT02594098 | Nov 2015 → Jan 2018 | atopic eczema | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 2 | NCT02599129 | Nov 2015 → Nov 2016 | alopecia areata | Icahn School of Medicine at Mount Sinai | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT02483234 | May 2015 → Jun 2018 | psoriasis, psoriatic arthritis | University of Erlangen-Nürnberg Medical School | Completed | No outcome recorded |
| Phase 2 | NCT02044848 | Feb → Sep 2014 | type 1 diabetes mellitus | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT01874340 | Jun 2013 → Apr 2014 | multiple sclerosis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01478360 | Mar 2012 → Nov 2014 | asthma | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 2 | NCT01433250 | Feb 2012 → Jun 2014 | multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01537432 | Jan 2012 → Dec 2014 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01359943 | Oct 2011 → Dec 2013 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01426789 | Aug 2011 → Feb 2014 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01364389 | Feb 2011 → Jan 2013 | inflammatory disease, polymyalgia rheumatica | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01250171 | Nov 2010 → Sep 2011 | dry eye syndrome | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01169844 | Jun 2010 → Nov 2012 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01132612 | May 2010 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01109940 | Apr 2010 → Dec 2012 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01071252 | Mar 2010 → Feb 2011 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01051817 | Dec 2009 → Apr 2012 | relapsing-remitting multiple sclerosis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01009281 | Oct 2009 → Aug 2010 | Crohn disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00941031 | Jul 2009 → Dec 2010 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00928512 | Jul 2009 → Mar 2011 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT00809159 | Mar 2009 → May 2011 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00809614 | Mar 2009 → Dec 2010 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00805480 | Dec 2008 → Sep 2010 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00770965 | Sep 2008 → Sep 2009 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00584740 | Aug 2008 → Aug 2010 | Crohn disease | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT00685399 | Jun 2008 → Sep 2013 | uveitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 381 trials · 37 met primary · 12 missed | ||||||
| Phase 3 | NCT06331312 | Jun 2024 → May 2028 expected | polymyalgia rheumatica | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05722522 | Aug 2023 → Oct 2024 | rotator cuff syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05758415 | Aug 2023 → Oct 2024 | rotator cuff syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT05767034 | Mar 2023 → Sep 2025 | polymyalgia rheumatica | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT05569174 | Dec 2022 → Dec 2024 | disease of the tendon | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05380453 | Sep 2022 → Feb 2026 | temporal arteritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT05232864 | Aug 2022 → Aug 2023 | lupus nephritis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT05206591 | Aug 2022 → Mar 2028 | spondyloarthropathy | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Business |
| Phase 3 | NCT04930094 | Oct 2021 → Apr 2025 | temporal arteritis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT04732117 | Jul 2021 → Apr 2024 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT04711902 | Jun 2021 → Jun 2022 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT04632927 | Dec 2020 → Oct 2024 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT04181762 | Jul 2020 → Sep 2023 | lupus nephritis | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT04237116 | Feb 2020 → Jun 2021 | NAFLD1, psoriasis | Novartis Pharmaceuticals | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT04209205 | Jan 2020 → May 2022 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT04156620 | Dec 2019 → Feb 2022 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03769168 | Jun 2019 → Nov 2024 | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03906136 | Jun 2019 → Feb 2022 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT03589885 | Dec 2018 → Nov 2019 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03668613 | Aug 2018 → Sep 2019 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03504852 | Jun 2018 → Sep 2019 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03259074 | Nov 2017 → Nov 2021 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT03136861 | Jun 2017 → Feb 2019 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT03031782 | May 2017 → Oct 2020 | enthesitis-related juvenile idiopathic arthritis, psoriasis-related juvenile idiopathic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02745080 | Apr 2017 → Dec 2019 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT03066609 | Feb → Dec 2017 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02748863 | Dec 2016 → Aug 2017 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02896127 | Oct 2016 → May 2018 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02721966 | Oct 2016 → Jun 2019 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02771210 | Aug 2016 → Dec 2019 | enthesitis, psoriatic arthritis, spondyloarthropathy | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT02826603 | Jun 2016 → Jul 2018 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02795416 | Jun 2016 → Mar 2017 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT02696031 | Apr 2016 → Jul 2019 | spondyloarthropathy | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02750592 | Mar 2016 → Jul 2017 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02778711 | Jan 2016 → Jun 2017 | allergic contact dermatitis | Tanja Todberg, MD | Unknown | No outcome recorded |
| Phase 3 | NCT02471144 | Sep 2015 → Dec 2018 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02404350 | Aug 2015 → Aug 2017 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02294227 | May 2015 → Feb 2016 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02595970 | May 2015 → Feb 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02159053 | May 2015 → Feb 2016 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT02409667 | May 2015 → Mar 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02394561 | Apr 2015 → Jun 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02474082 | Apr 2015 → Jun 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02362789 | Jan 2015 → Jul 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02267135 | Sep 2014 → Dec 2015 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01989468 | Apr 2014 → May 2015 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02559622 | Apr 2014 → Apr 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT03358134 | Mar 2014 → Jul 2017 | spondyloarthropathy | Academic Medical Center - University of Amsterdam | Completed | No outcome recorded |
| Phase 3 | NCT02074982 | Feb 2014 → Jun 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02008916 | Jan 2014 → Feb 2015 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT02008890 | Dec 2013 → Nov 2014 | palmoplantar pustulosis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01863732 | Nov 2013 → Mar 2018 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01961609 | Oct 2013 → Jul 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01900782 | Oct 2013 → Jun 2015 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01892436 | Sep 2013 → Jan 2018 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01952015 | Aug 2013 → Mar 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01807520 | Jun 2013 → Jan 2017 | — | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01806597 | Jun 2013 → Nov 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01752634 | Apr 2013 → May 2014 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01649375 | Oct 2012 → Aug 2014 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01636687 | Oct 2012 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01770379 | Oct 2012 → May 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT01640951 | Sep 2012 → May 2017 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01544595 | Jun 2012 → Jun 2017 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01555125 | May 2012 → Oct 2016 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01412944 | Dec 2011 → Apr 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01358175 | Oct 2011 → Dec 2014 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01392326 | Sep 2011 → Oct 2014 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01350804 | Sep 2011 → Feb 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01377012 | Aug 2011 → Sep 2015 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01406938 | Aug 2011 → May 2013 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01365455 | Jun 2011 → Apr 2013 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01358578 | Jun 2011 → Jul 2013 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01327664 | Mar 2011 → May 2014 | uveitis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 3 | NCT01103024 | Dec 2010 → Feb 2011 | uveitis | Novartis | Withdrawn | No outcome recorded |
| Phase 3 | NCT01090310 | Aug 2010 → Jul 2011 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01095250 | Apr → Oct 2010 | uveitis | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT01093846 | Mar 2010 → Jan 2011 | uveitis | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01032915 | Feb 2010 → Jun 2011 | uveitis | Novartis Pharmaceuticals | Terminated | Missed primary |
| Phase 3 | NCT00995709 | Oct 2009 → Jul 2010 | Behcet disease | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 435 trials · 2 met primary · 4 missed | ||||||
| Phase 4 | NCT07770646 | Sep 2026 → Sep 2028 expected | spondyloarthropathy | The University of Texas Health Science Center, Houston | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07352566 | Aug 2026 → Jun 2030 expected | atopic eczema, psoriasis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07704190 | Jul 2026 → Dec 2028 expected | atherosclerotic cardiovascular disease, cardiovascular-kidney-metabolic syndrome, carotid stenosis, chronic kidney disease +4 | Peking University Third Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07489573 | Jun 2026 → Sep 2029 expected | hidradenitis suppurativa | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT07149792 | Jul 2025 → Dec 2026 expected | psoriasis, psoriatic arthritis | Taichung Veterans General Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06833112 | Feb 2025 → Aug 2027 expected | ankylosing spondylitis | The Affiliated Hospital Of Guizhou Medical University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06398106 | Dec 2024 → Mar 2028 expected | psoriasis | University Hospital, Ghent | Recruiting | No outcome recorded |
| Phase 4 | NCT05303285 | Jun 2024 → Aug 2026 overdue | ankylosing spondylitis | Tongji Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT04239859 | Jan 2024 → Dec 2027 expected | psoriasis | Singapore General Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05622708 | Mar 2023 → Feb 2028 expected | spondyloarthropathy | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 4 | NCT05527444 | Mar 2022 → Dec 2024 | ankylosing spondylitis | Qilu Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 4 | NCT04535999 | Feb 2022 → May 2025 | psoriasis | University of Pennsylvania | Completed | No outcome recorded |
| Phase 4 | NCT05080218 | Nov 2021 → Apr 2024 | psoriatic arthritis, spondyloarthropathy | Jeffrey Curtis | Completed | No outcome recorded |
| Phase 4 | NCT05891964 | Jul 2021 → Jun 2022 | psoriasis | Jinnah Postgraduate Medical Centre | Completed | No outcome recorded |
| Phase 4 | NCT04717466 | Jun 2021 → May 2024 | psoriasis | University of Miami | Completed | No outcome recorded |
| Phase 4 | NCT04996485 | Mar 2021 → Mar 2023 | inherited ichthyosis | National Medical Research Center for Children's Health, Russian Federation | Unknown | No outcome recorded |
| Phase 4 | NCT04638647 | Dec 2020 → Jan 2030 expected | immune dysregulation, autoimmunity, and autoinflammation | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 4 | NCT04488185 | Nov 2020 → Mar 2021 | psoriasis | Novartis Pharmaceuticals | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04340076 | Aug 2020 → Jan 2025 | psoriasis | Radboud University Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT04469829 | Aug 2020 → Dec 2021 | metabolic syndrome X, psoriasis | University of Verona | Unknown | No outcome recorded |
| Phase 4 | NCT03623867 | May 2020 → Sep 2022 | psoriatic arthritis | Chinese University of Hong Kong | Completed | No outcome recorded |
| Phase 4 | NCT04571567 | Dec 2019 → Feb 2022 | psoriasis | Saakshi Khattri | Completed | No outcome recorded |
| Phase 4 | NCT04887597 | Mar 2019 → Mar 2022 | enthesitis, psoriatic arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 4 | NCT03639740 | Jan 2019 → Feb 2021 | ankylosing spondylitis | Professor Mikkel Østergaard | Unknown | Missed primary |
| Phase 4 | NCT03445845 | Dec 2018 → Sep 2024 | spondyloarthropathy | University Hospital of Saint-Etienne | Completed | No outcome recorded |
| Phase 4 | NCT03440736 | Feb 2018 → Nov 2021 | metabolic syndrome X, psoriasis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 4 | NCT03307447 | Dec 2017 → Sep 2021 | psoriasis | Narrows Institute for Biomedical Research | Unknown | No outcome recorded |
| Phase 4 | NCT03055494 | Apr 2017 → Apr 2018 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT03020199 | Mar 2017 → Nov 2021 | psoriasis | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 4 | NCT05676333 | Oct 2016 → Dec 2017 | vitiligo | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02592018 | Oct 2016 → Dec 2018 | psoriasis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 4 | NCT02763046 | May 2016 → Sep 2019 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 4 | NCT02752776 | Mar 2016 → Mar 2018 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02690701 | Feb 2016 → Apr 2017 | psoriasis | Novartis Pharmaceuticals | Completed | Missed primary |
| Phase 4 | NCT02547714 | Jun 2015 → May 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06707246 | Dec 2024 → Oct 2026 expected | hidradenitis suppurativa | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| — | NCT05503875 | Jan 2023 → Dec 2027 expected | psoriasis | Second Affiliated Hospital, School of Medicine, Zhejiang University | Recruiting | No outcome recorded |
| Comparator or background therapy28 trials | ||||||
| Phase 1 | NCT06126718 Comparator | Feb → Aug 2024 | psoriasis | BioRay Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07054970 Comparator | Jan → Aug 2024 | — | Celltrion | Completed | Met primary |
| Phase 1 | NCT04711343 Comparator | Jun 2022 → May 2023 | psoriasis | Bio-Thera Solutions | Completed | No outcome recorded |
| Phase 1 | NCT04589026 Comparator | Oct 2020 → May 2021 | — | Janssen Research & Development, LLC | Completed | No outcome recorded |
| Phase 1 | NCT01828086 Comparator | Jun 2013 → Oct 2015 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT03384745 Comparator | Jul 2018 → Jun 2019 | psoriasis | Bond Avillion 2 Development LP | Completed | Met primary |
| Phase 3 | NCT06945107 Comparator | May 2025 → Jun 2026 overdue | psoriasis | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06630559 Comparator | May 2025 → Feb 2026 overdue | psoriasis | Celltrion | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06398652 Comparator | Aug 2024 → Jun 2025 | psoriasis | Taizhou Mabtech Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT06110676 Comparator | Aug 2023 → Apr 2025 | psoriasis | Livzon Pharmaceutical Group Inc. | Unknown | No outcome recorded |
| Phase 3 | NCT05377944 Comparator | Oct 2022 → May 2024 | psoriasis | Bio-Thera Solutions | Completed | Met primary |
| Phase 3 | NCT04737330 Comparator | Nov 2021 → May 2023 | endocrine exophthalmos | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04179175 Comparator | Mar 2020 → May 2023 overdue | hidradenitis suppurativa | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03713632 Comparator | Feb 2019 → Sep 2021 | hidradenitis suppurativa | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03713619 Comparator | Jan 2019 → Oct 2021 | hidradenitis suppurativa | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT03535194 Comparator | Jun 2018 → Mar 2020 | psoriasis | Eli Lilly and Company | Completed | Met primary |
| Phase 3 | NCT03536884 Comparator | Jun 2018 → Sep 2019 | psoriasis | UCB Biopharma SRL | Completed | Met primary |
| Phase 3 | NCT03478787 Comparator | May 2018 → Jul 2020 | psoriasis | AbbVie | Completed | Met primary |
| Phase 3 | NCT03090100 Comparator | Apr 2017 → Aug 2018 | psoriasis | Janssen Research & Development, LLC | Completed | Met primary |
| Phase 3 | NCT02662985 Comparator | Aug 2016 → Nov 2020 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02474069 Comparator | Feb 2015 → Sep 2016 | psoriasis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT07485764 Background | Jun 2026 overdue | obesity disorder, psoriasis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07261072 Comparator | Dec 2025 → Nov 2026 expected | hidradenitis suppurativa | Peking Union Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT03350815 Comparator | Mar 2018 → Mar 2021 | ankylosing spondylitis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02798211 Comparator | Jun 2016 → Dec 2018 | psoriatic arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT02144857 Comparator | May 2014 → Sep 2023 | psoriasis | University of Athens | Unknown | No outcome recorded |
| — | NCT06729463 Comparator | Dec 2024 → Mar 2025 | psoriasis, psoriatic arthritis | South Valley University | Completed | No outcome recorded |
| — | NCT05583604 Background | — | hidradenitis suppurativa | Novartis Pharmaceuticals | Available | No outcome recorded |
News releases announcing trial results or a regulatory action · 93
| Date | Issuer | Release |
|---|---|---|
| 2026-09-18 | Novartis Pharmaceuticals | Regulatory Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR) novartis.com ↗
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Cosentyx® (secukinumab) in polymyalgia rheumatica (PMR). |
| 2026-06-18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION irasia.com ↗
NMPA ACCEPTS MARKETING AUTHORISATION APPLICATION FOR SECUKINUMAB INJECTION |
| 2026-06-03 | Novartis Pharmaceuticals | Results Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients novartis.com ↗
Novartis presented today new Cosentyx® (secukinumab) data in polymyalgia rheumatica (PMR) demonstrating a statistically significant, clinically meaningful difference in sustained remission rates vs placebo and significant steroid sparing 8 . |
| 2026-03-13 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa novartis.com ↗ |
| 2025-12-18 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Results VOLUNTARY ANNOUNCEMENT - TOPLINE RESULTS OBTAINED FROM PHASE III CLINICAL TRIAL OF SECUKINUMAB INJECTION irasia.com ↗
TOPLINE RESULTS OBTAINED FROM PHASE III CLINICAL TRIAL OF SECUKINUMAB INJECTION |
| 2025-10-22 | Novartis Pharmaceuticals | Results Novartis Cosentyx® meets primary and all secondary endpoints in Phase III trial in patients with polymyalgia rheumatica (PMR) novartis.com ↗
Novartis today announced that Cosentyx® (secukinumab) met the primary endpoint and all secondary endpoints in the Phase III REPLENISH trial 1 . |
| 2025-07-17 | Novartis Pharmaceuticals | Results Novartis reports strong Q2 with double-digit sales growth and core margin expansion; raises FY 2025 core operating income guidance novartis.com ↗
In the Phase III GCAptAIN study, Cosentyx did not demonstrate a statistically significant improvement in sustained remission compared to placebo in adults with newly diagnosed or relapsing giant cell arteritis (GCA). |
| 2025-07-03 | Novartis Pharmaceuticals | Results Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA) novartis.com ↗
Cosentyx did not demonstrate a statistically significant improvement in sustained remission at Week 52 compared to placebo. |
| 2023-11-01 | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Regulatory VOLUNTARY ANNOUNCEMENT - SECUKINUMAB INJECTION OBTAINS CLINICAL TRIAL APPROVAL irasia.com ↗
The board of directors (the “Board”) of CSPC Pharmaceutical Group Limited (the “Company”, together with its subsidiaries, the “Group”) is pleased to announce that the Secukinumab Injection (the “Product”) developed by the Group has obtained approval granted by the National Medical Products Administration of the People’s Republic of China to conduct clinical trials in China. |
| 2023-10-31 | Novartis Pharmaceuticals | Regulatory FDA approves Novartis Cosentyx® as the first new biologic treatment option for hidradenitis suppurativa patients in nearly a decade novartis.com ↗
Basel, October 31, 2023 — Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) to treat moderate to severe hidradenitis suppurativa (HS) in adults. |
| 2023-06-01 | Novartis Pharmaceuticals | Regulatory Novartis receives European approval for Cosentyx® as first and only IL-17A inhibitor for hidradenitis suppurativa novartis.com ↗
Basel, June 1, 2023 — Novartis announced today that the European Commission (EC) has approved Cosentyx ® (secukinumab) for use in adults with active moderate to severe hidradenitis suppurativa (HS) and an inadequate response to conventional systemic HS therapy 7 . |
| 2023-04-26 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® gains positive CHMP opinion for hidradenitis suppurativa novartis.com ↗ |
| 2023-03-17 | Janssen Research & Development, LLC | Results TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis jnj.com ↗
Analysis of real-world data from the IBM MarketScan Research Databases from July 13, 2017, to May 1, 2021, showed TREMFYA was associated with greater persistence (i.e., longer median time to index treatment discontinuation) compared to secukinumab and ixekizumab among bio-naïve patients:[1] |
| 2023-03-17 | Janssen Research & Development, LLC | Results TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis jnj.com ↗
TREMFYA® (guselkumab) Real-World Data Analyses Show Greater Treatment Persistence Than IL-17s in Both Bio-naïve and Bio-experienced Patients Living With Moderate to Severe Plaque Psoriasis |
| 2023-02-04 | Novartis Pharmaceuticals | Results Patients with hidradenitis suppurativa experienced sustained efficacy and symptom improvement at one year when treated with Novartis Cosentyx® novartis.com ↗ |
| 2022-09-10 | Novartis Pharmaceuticals | Results Novartis Cosentyx® shows clinically meaningful symptom improvements in patients with hidradenitis suppurativa in pivotal Phase III trials novartis.com ↗
Novartis announced the results from two pivotal, Phase III studies (SUNSHINE and SUNRISE), in which Cosentyx ® (secukinumab) demonstrated rapid and sustained relief from the common clinical signs and symptoms of moderate-to-severe hidradenitis suppurativa (HS) with a favorable safety profile 5,6 . |
| 2022-06-27 | Novartis Pharmaceuticals | Regulatory Cosentyx® (secukinumab) receives expanded approvals in EU for use in childhood arthritic conditions novartis.com ↗ |
| 2022-05-20 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® (secukinumab) receives positive CHMP opinion for expanded use in childhood arthritic conditions novartis.com ↗ |
| 2022-05-09 | MoonLake Immunotherapeutics AG | Results MoonLake Immunotherapeutics announces the publication of new long-term disease control data from a Phase 2b Psoriasis trial of the Nanobody® sonelokimab moonlaketx.com ↗
The dataset shows that with the optimal dose of sonelokimab (120mg Q4W) more patients achieved complete skin clearance at week 24 than in patients treated with the IL-17A inhibiting antibody secukinumab (56.9% vs. 34.0% respectively, exploratory P = 0.019). |
| 2021-12-23 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® receives FDA approval for the treatment of children and adolescents with enthesitis-related arthritis and psoriatic arthritis novartis.com ↗
today announced the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment of active enthesitis-related arthritis (ERA) in four years and older, and active juvenile psoriatic arthritis (JPsA) in patients two years and older 1 . |
| 2021-12-02 | Novartis Pharmaceuticals | Results Novartis R&D day spotlights attractive growth profile, underpinned by strong in-market brands, 20 potential high value pipeline assets, and technology platforms novartis.com ↗
Cosentyx met primary efficacy endpoint in two hidradenitis suppurativa Ph3 studies, and ianalumab demonstrated efficacy in Ph2b Sjögren’s study |
| 2021-11-08 | Novartis Pharmaceuticals | Results Novartis presents positive Phase III results for Cosentyx® in children with active enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) at ACR 2021 novartis.com ↗
Treatment with Cosentyx ® (secukinumab) resulted in a 72% reduced flare risk versus placebo, with improvement in disease activity over two years across both enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) 1 . |
| 2021-09-29 | Novartis Pharmaceuticals | Results New data reinforce efficacy and convenience of Novartis Cosentyx® (secukinumab) 300 mg autoinjector in adults with psoriasis novartis.com ↗
New findings show Cosentyx ® (secukinumab) 300 mg single dose autoinjector (the UnoReady ® pen) resulted in superior efficacy vs placebo 1 |
| 2021-08-17 | Novartis Pharmaceuticals | Regulatory Novartis secures new approval in China for Cosentyx® (secukinumab) in pediatric psoriasis novartis.com ↗
China National Medical Products Administration (NMPA) approval reinforces that Cosentyx ® (secukinumab) is safe and effective for children and adults with psoriasis |
| 2021-06-02 | Novartis Pharmaceuticals | Results Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021 novartis.com ↗
Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx ® (secukinumab) significantly delayed time to flare vs placebo ( P <.001) in pediatric patients with juvenile psoriatic arthritis (JPsA) and enthesitis-related arthritis (ERA) – two subtypes of juvenile idiopathic arthritis (JIA) 2 . |
| 2021-06-01 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis novartis.com ↗
This is the first approval for Cosentyx in a pediatric population in the US. |
| 2021-04-23 | Eli Lilly and Company | Results Taltz® Delivers More Cumulative Days with Completely Clear Skin for Adults with Psoriasis Compared to Seven Other Biologics in Novel Network Meta-Analysis lilly.com ↗
Taltz offered patients with psoriasis the greatest number of cumulative days of completely clear skin compared to adalimumab, brodalumab, etanercept, guselkumab, risankizumab, secukinumab and ustekinumab. |
| 2021-02-26 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® gains EU label update for first-of-its-kind MAXIMISE data in axial manifestations of psoriatic arthritis novartis.com ↗ |
| 2020-11-05 | Novartis Pharmaceuticals | Results Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study novartis.com ↗
Novartis, a leader in rheumatology and immuno-dermatology, today announced 12-week results from the first-of-its-kind Phase IIIb ULTIMATE randomized controlled trial, which demonstrated the significant treatment response of Cosentyx ® (secukinumab) on synovitis (joint lining inflammation) in psoriatic arthritis (PsA) versus placebo. |
| 2020-10-29 | Novartis Pharmaceuticals | Results Novartis presents latest Phase III data reinforcing Cosentyx® as a first-line systemic treatment in pediatric psoriasis novartis.com ↗
Novartis, a leader in immuno-dermatology and rheumatology, today announced data from two pivotal international Phase III studies, which show Cosentyx ® (secukinumab) provides fast and strong skin clearance and significant improvement in quality of life in children and adolescents aged 6 to <18 years with moderate-to-severe plaque psoriasis. |
| 2020-08-03 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis novartis.com ↗ |
| 2020-07-17 | Eli Lilly and Company | Results Lilly's Mirikizumab Superior to Cosentyx® (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis lilly.com ↗ |
| 2020-06-26 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile novartis.com ↗
Novartis, a leader in immuno-dermatology and rheumatology, today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx ® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and adolescents aged 6 to <18 years. |
| 2020-06-17 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® receives FDA approval for new indication to treat active non-radiographic axial spondyloarthritis novartis.com ↗ |
| 2020-06-12 | AbbVie | Results AbbVie Presents New Late-Breaking Data Showing SKYRIZI® (risankizumab-rzaa) Achieves Superior Rates of Complete Skin Clearance Versus COSENTYX® (secukinumab) at 52 Weeks abbvie.com ↗
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new late-breaking Phase 3b head-to-head data showing superior rates of skin clearance for SKYRIZI ® (risankizumab-rzaa) to COSENTYX ® (secukinumab) at week 52. |
| 2020-06-04 | Novartis Pharmaceuticals | Results Novartis PREVENT data show Cosentyx® helps patients realize early and lasting relief in axial spondyloarthritis novartis.com ↗
The study found patients treated with Cosentyx 150 mg showed significant and sustained improvements in signs and symptoms of non-radiographic axial spondyloarthritis (nr-axSpA) at 52 weeks. |
| 2020-04-29 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrum novartis.com ↗
Novartis, a leader in rheumatology and immuno-dermatology, today announced the European Commission (EC) has approved Cosentyx ® (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA). |
| 2020-03-27 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® gains positive CHMP opinion for new indication in the axial spondyloarthritis spectrum novartis.com ↗ |
| 2020-01-31 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx® builds on its axSpA leadership with US label update for dosing flexibility in ankylosing spondylitis novartis.com ↗
“This approval gives clinicians added flexibility to ensure patients are able to achieve the best response to treatment and experience full relief from the signs and symptoms of AS,” said Todd Fox, Global Head of Medical Affairs Immunology, Hepatology and Dermatology at Novartis. |
| 2020-01-14 | AbbVie | Results New Head-to-Head Phase 3 Data Show SKYRIZI™ (risankizumab) Superior to Cosentyx® (secukinumab) Across Primary and All Ranked Secondary Endpoints in Adults with Moderate to Severe Plaque Psoriasis at 52 Weeks abbvie.com ↗
AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that SKYRIZI ™ met both primary and all ranked secondary endpoints, including superiority at week 52, versus Cosentyx ® in a head-to-head Phase 3 study. |
| 2019-11-12 | Novartis Pharmaceuticals | Results New Novartis PREVENT data show Cosentyx® delivers early relief in axial spondyloarthritis novartis.com ↗
The ongoing trial met its primary endpoint of ASAS40 at Week 16, with 42.2% of nr-axSpA patients treated with Cosentyx 150 mg showing a significant and clinically meaningful reduction in disease activity versus placebo (42.2% vs 29.2%: p<0.05)[1]. |
| 2019-11-01 | Novartis Pharmaceuticals | Results Novartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritis novartis.com ↗
Novartis, a leader in rheumatology and immuno-dermatology, today announced results from the EXCEED head-to-head trial comparing Cosentyx ® (secukinumab) to Humira ® * (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. |
| 2019-10-24 | Novartis Pharmaceuticals | Regulatory Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in ankylosing spondylitis novartis.com ↗
Basel, October 24, 2019 – Novartis, a leader in rheumatology and immuno-dermatology, announced today that the European Commission (EC) has approved a label update for the up-titration of Cosentyx (secukinumab) to 300 mg for patients with active ankylosing spondylitis (AS). |
| 2019-10-10 | Novartis Pharmaceuticals | Results Novartis data show Cosentyx® treatment results in rapid and sustained resolution of signs and symptoms of psoriatic arthritis in patients with and without enthesitis novartis.com ↗
Results from a pooled analysis of two Phase 3 studies, show that patients treated with Cosentyx (n=477) had a faster time to complete resolution of enthesitis than those receiving placebo (n=235) |
| 2019-10-09 | Novartis Pharmaceuticals | Results Novartis real-world evidence confirms high efficacy, long-term response and favorable safety profile of Cosentyx® in clinical practice novartis.com ↗
The studies report on the real-world sustained efficacy, favorable safety profile, and impact on quality of life of Cosentyx over the long-term up to 2.5 years [1-6] |
| 2019-10-02 | Novartis Pharmaceuticals | Results Novartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrum novartis.com ↗
The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 52, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. |
| 2019-09-17 | Novartis Pharmaceuticals | Results Novartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritis novartis.com ↗
The ongoing Phase III trial met its primary endpoint of ASAS40 at Week 16, showing a significant and clinically meaningful reduction in disease activity for patients treated with Cosentyx versus placebo. |
| 2019-06-26 | Novartis Pharmaceuticals | Results Novartis highlights new publication showing IL-17A antibody Cosentyx® improves inflammation and rapidly suppresses IL-23 in plaque psoriasis novartis.com ↗
New data show that Cosentyx modulates gene expression leading to substantial improvement of inflammation, as early as Week 12 by reversing plaque histopathology in the majority of patients[1] |
| 2019-06-17 | Novartis Pharmaceuticals | Results New analysis of Novartis data confirms that Cosentyx® demonstrates durable comprehensive treatment across psoriatic disease novartis.com ↗
Additional new 5 year data with Cosentyx ® confirmed low immunogenicity with rates year-over-year consistently below 1% in patients with moderate to severe plaque psoriasis[4] |
| 2019-06-12 | Novartis Pharmaceuticals | Results Novartis Cosentyx® first to show efficacy in all key manifestations of psoriatic arthritis novartis.com ↗
The ongoing 52-week Phase IIIb trial met both its primary and key secondary endpoint with 63.1% of Cosentyx 300 mg and 66.3% of Cosentyx 150 mg patients achieving ASAS20 at Week 12 (versus 31.3% for placebo) respectively. |
| 2019-06-12 | Novartis Pharmaceuticals | Results Cosentyx® provides long-lasting inhibition of radiographic progression in psoriatic arthritis, new Novartis data show novartis.com ↗
These data demonstrate that 89.5% (300mg), 82.3% (150mg) and 81.1% (150mg no loading dose [LD]) of PsA patients treated with Cosentyx found no radiographic progression at 2 years. |
| 2019-04-02 | Novartis Pharmaceuticals | Regulatory Novartis first-in-class Cosentyx® approved in China for psoriasis patients novartis.com ↗
Novartis, a global leader in immuno-dermatology and rheumatology, announced today that the China Health Authority NMPA approved Cosentyx ® (secukinumab), the first-in-class interleukin-17A (IL-17A) inhibitor for moderate-to-severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy. |
| 2019-03-05 | Novartis Pharmaceuticals | Results Novartis Cosentyx® shows superior improvements in psoriasis patients' quality of life versus Janssen's IL-23 Stelara®* novartis.com ↗
New CLARITY data show over two-thirds of Cosentyx treated patients with moderate to severe psoriasis reported no impact of skin disease on their QoL up to Week 16 compared to Stelara ® * (ustekinumab) treated patients (68.4% versus 55.9%, respectively)[1]. |
| 2019-03-04 | Novartis Pharmaceuticals | Results Novartis data confirm rapid response and high efficacy of Cosentyx® in psoriasis patients for first time in China novartis.com ↗
Phase III study shows close to 9/10 patients who received Cosentyx® 300mg achieved clear or almost clear skin during the first 16 weeks of treatment (87%), with rapid onset of relief seen as early as week 3[1] |
| 2018-12-12 | Janssen Research & Development, LLC | Results New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 jnj.com ↗
New Phase 3 data demonstrate superiority of TREMFYA® (guselkumab) vs Cosentyx® (secukinumab) in delivering PASI 90 responses in the treatment of moderate to severe plaque psoriasis at week 48 |
| 2018-10-26 | Novartis Pharmaceuticals | Regulatory Novartis receives approval for Cosentyx® label update in Europe to include dosing flexibility in psoriatic arthritis novartis.com ↗
Basel, October 26, 2018 - Novartis, a leader in immuno-dermatology and rheumatology, announced today that the European Commission (EC) has approved a label update for Cosentyx ® (secukinumab). |
| 2018-10-16 | Novartis Pharmaceuticals | Results Novartis 5-year data in psoriatic arthritis and ankylosing spondylitis reinforces Cosentyx® leadership in spondyloarthritis novartis.com ↗
New long-term data from FUTURE 1 and MEASURE 1 confirm that Cosentyx provides sustained improvements in the signs and symptoms of PsA and AS out to five years[1],[2]. |
| 2018-09-13 | Novartis Pharmaceuticals | Results Novartis real-world evidence confirms efficacy and safety benefits of Cosentyx® in daily life for psoriasis patients novartis.com ↗
Novartis, a leader in immuno-dermatology, announced today new data from multiple real-world sources in moderate-to-severe plaque psoriasis, which confirm Cosentyx ® (secukinumab) efficacy and safety in clinical practice is comparable to previously reported clinical studies[1]-[4]. |
| 2018-02-16 | Novartis Pharmaceuticals | Results Novartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis novartis.com ↗
Two thirds of patients on Cosentyx ® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows[1] |
| 2018-02-16 | Novartis Pharmaceuticals | Results Novartis new Cosentyx® data confirms robust efficacy and quality of life improvements in scalp psoriasis novartis.com ↗
Novartis has presented new Cosentyx ® (secukinumab) data from the prospective Phase III SCALP study which showed significant improvement in skin clearance with Cosentyx in patients with scalp psoriasis. |
| 2018-02-08 | Novartis Pharmaceuticals | Regulatory Novartis receives FDA approval for Cosentyx® label update to include moderate-to-severe scalp psoriasis novartis.com ↗
Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx ® (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis[1]. |
| 2018-01-16 | Novartis Pharmaceuticals | Results Novartis new data reinforces superiority of Cosentyx® versus Stelara®* in achieving skin clearance for psoriasis patients novartis.com ↗
Results from CLARITY study show Cosentyx ® (secukinumab) was significantly more effective than Stelara ®* (ustekinumab) in delivering clear and almost clear skin at 12 weeks and at 16 weeks[1] |
| 2017-11-30 | Novartis Pharmaceuticals | Results Novartis' Cosentyx® is first biologic to show long-term efficacy in nail and palmoplantar psoriasis, which can impact up to 90% of psoriasis patients novartis.com ↗
Novartis, a global leader in Immunology & Dermatology, announced today first-of-its-kind long-term data showing that Cosentyx ® (secukinumab) provided sustained improvements in nail and palmoplantar psoriasis out to 2.5 years[1],[2]. |
| 2017-11-07 | Novartis Pharmaceuticals | Results Novartis announces study data demonstrating Cosentyx® reduced signs and symptoms of psoriatic arthritis while inhibiting progression of joint structural damage novartis.com ↗ |
| 2017-11-06 | Novartis Pharmaceuticals | Results Novartis seeks leadership with Cosentyx® showing no radiographic progression in ankylosing spondylitis at 4 years novartis.com ↗
This study is unique as these data show, for the first time with any biologic, that almost 80 percent of AS patients treated with Cosentyx have no radiographic progression (mSASSS <2) of the spine at 4 years[1]. |
| 2017-09-13 | Novartis Pharmaceuticals | Results Novartis' Cosentyx® sets new benchmark in psoriasis with robust 5-year sustained Phase III efficacy and safety data novartis.com ↗
Novartis announced today, first of its kind Phase III data showing Cosentyx ® (secukinumab) delivered high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis at 5 years[1]. |
| 2017-07-14 | Novartis Pharmaceuticals | Results Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing sustained efficacy and safety profile in psoriasis novartis.com ↗
Basel, July 14, 2017 - Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis[1]. |
| 2017-07-06 | Novartis Pharmaceuticals | Regulatory Novartis receives approval in the EU for Cosentyx label update, includes long term superiority data versus Stelara in psoriasis novartis.com ↗
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has approved a label update for Cosentyx ® (secukinumab), the first interleukin-17A (IL-17A) approved to treat psoriasis. |
| 2017-06-15 | Novartis Pharmaceuticals | Results Novartis' Cosentyx shows sustained improvements in signs and symptoms for both AS and PsA in up to 80% of patients at 3 years novartis.com ↗
Novartis announced today data showing Cosentyx ® (secukinumab) shows sustained improvements in the signs and symptoms for active ankylosing spondylitis (AS) at 3 years[1], consistent with previous findings in active psoriatic arthritis (PsA) at 3 years[2]. |
| 2017-03-21 | Novartis Pharmaceuticals | Results Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis novartis.com ↗
Novartis today announced new data suggesting, for the first time, that Cosentyx ® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1]. |
| 2017-03-06 | Novartis Pharmaceuticals | Results Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a treatment pause novartis.com ↗
This new analysis shows that if psoriasis patients relapse during treatment pauses, the majority can achieve previous high levels of efficacy after only 16 weeks of retreatment with Cosentyx[1]. |
| 2016-11-14 | Novartis Pharmaceuticals | Results Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain novartis.com ↗ |
| 2016-10-01 | Novartis Pharmaceuticals | Results Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients novartis.com ↗
Novartis announced today new data showing Cosentyx ® (secukinumab) delivers high and long-lasting skin clearance in patients with moderate-to-severe plaque psoriasis out to 4 years of treatment[1]. |
| 2016-06-08 | Novartis Pharmaceuticals | Results Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016 novartis.com ↗
This includes new long-term analyses suggesting Cosentyx ® (secukinumab) may lead to higher responses than Humira ® * (adalimumab) in improving the signs and symptoms of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) at 52 weeks[3],[4]. |
| 2016-04-21 | The Medicines Company | Results Novartis erzielt im ersten Quartal trotz Verlust der Exklusivrechte an Gleevec solide Ergebnisse und investiert in Neueinführungen zugunsten langfristigen Wachstums novartis.com ↗
Neue Daten aus der Vergleichsstudie CLEAR bei Erwachsenen mit mittelschwerer bis schwerer Psoriasis belegten, dass Cosentyx (Secukinumab) Stelara® nach 52 Wochen nach wie vor überlegen ist in Bezug auf die Erhaltung eines nahezu symptomfreien oder symptomfreien Hautbildes (PASI 90 bis PASI 100). |
| 2016-03-05 | Novartis Pharmaceuticals | Results Novartis' Cosentyx superior to Stelara in delivering long-lasting skin clearance (PASI 90) for psoriasis patients at 52 weeks novartis.com ↗
Novartis announced today new late-breaking data from the head-to-head CLEAR study, demonstrating that Cosentyx (secukinumab) remains superior to Stelara (ustekinumab) in achieving sustained skin clearance (PASI 90 response) at 52 weeks for adults living with moderate-to-severe psoriasis. |
| 2016-01-15 | Novartis Pharmaceuticals | Regulatory Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US novartis.com ↗
Novartis announced today that the US Food and Drug Administration (FDA) has approved Cosentyx ® (secukinumab) for the treatment of two new indications - adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). |
| 2015-12-23 | Novartis Pharmaceuticals | Results Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients novartis.com ↗
These pivotal studies demonstrated significant clinical improvements with Cosentyx versus placebo in the signs and symptoms of active AS - a long-term, painful and debilitating inflammation of the spine[2],[3]. |
| 2015-11-23 | Novartis Pharmaceuticals | Regulatory Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis novartis.com ↗
Novartis announced today that the European Commission (EC) has approved Cosentyx ® (secukinumab) for the treatment of people living with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). |
| 2015-11-08 | Novartis Pharmaceuticals | Results Novartis presents new two year data for Cosentyx® showing no progression in joint damage in 84% of psoriatic arthritis patients novartis.com ↗
Novartis announced today new results for Cosentyx ® (secukinumab) showing no further progression in joint damage in 84% of patients with psoriatic arthritis (PsA). |
| 2015-11-08 | Novartis Pharmaceuticals | Results New two year data for Novartis' Cosentyx® show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of patients with ankylosing spondylitis novartis.com ↗
Novartis announced today late-breaking two year results for Cosentyx ® (secukinumab) showing up to 80% of patients with ankylosing spondylitis (AS) had no radiographic progression in the spine on x-ray assessment[1]. |
| 2015-10-23 | Novartis Pharmaceuticals | Regulatory Novartis receives positive CHMP opinion for the first IL-17A inhibitor Cosentyx(TM) to treat ankylosing spondylitis and psoriatic arthritis novartis.com ↗
Novartis announced today that the Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Cosentyx (TM) (secukinumab) in Europe to treat ankylosing spondylitis (AS) and psoriatic arthritis (PsA) patients. |
| 2015-10-10 | Novartis Pharmaceuticals | Results Novartis presents new data showing that the majority of patients are able to maintain clear or almost clear skin with Cosentyx across 3 years novartis.com ↗
Novartis announced today new late-breaking data demonstrating that Cosentyx TM (secukinumab) provides high levels of skin clearance and sustained efficacy in patients with moderate-to-severe plaque psoriasis while maintaining a favorable safety profile across three years[1]. |
| 2015-09-30 | Novartis Pharmaceuticals | Results Novartis announces NEJM publication of secukinumab Phase III data confirming significant efficacy in patients with psoriatic arthritis novartis.com ↗
In this study, secukinumab met the primary endpoint with a 20% reduction in the American College of Rheumatology response criteria (ACR 20) at Week 24 showing rapid and significant clinical improvements versus placebo[1]. |
| 2015-06-29 | Novartis Pharmaceuticals | Results Novartis announces publication in The Lancet showing sustained efficacy with secukinumab over one year in psoriatic arthritis patients novartis.com ↗
Novartis announced today that new one year results from the pivotal Phase III FUTURE 2 study of secukinumab in psoriatic arthritis (PsA) were published in The Lancet following fast-track review. |
| 2015-06-11 | Novartis Pharmaceuticals | Results Novartis presents new data at WCD demonstrating significant efficacy of Cosentyx® in patients with psoriasis of the nails, palms and soles novartis.com ↗
Novartis announced today that Cosentyx ® (secukinumab) met the primary endpoints in two new clinical studies, showing superior efficacy compared to placebo in patients with psoriasis of the palms, soles and nails, all difficult-to-treat locations of plaque psoriasis. |
| 2015-06-10 | Novartis Pharmaceuticals | Results Novartis announces new one-year results demonstrating sustained secukinumab efficacy in ankylosing spondylitis patients novartis.com ↗
Novartis announced today new one-year study results from the MEASURE 2 pivotal Phase III study of secukinumab in ankylosing spondylitis (AS). |
| 2015-04-23 | Novartis Pharmaceuticals | Results Novartis delivered sales growth (cc), significant margin expansion (cc) and strong innovation in Q1[1]; now with a more focused portfolio novartis.com ↗
Two-year results for Cosentyx (secukinumab) demonstrated a strong and sustained efficacy with a favorable safety profile for the treatment of psoriasis. |
| 2015-03-21 | Novartis Pharmaceuticals | Results Novartis' Cosentyx(TM) two-year data shows sustained effect and favorable safety profile in psoriasis patients novartis.com ↗
Novartis today announced new two-year results demonstrating strong and sustained efficacy with Cosentyx(TM) (secukinumab) with a favorable safety profile for the treatment of psoriasis patients[1]. |
| 2015-03-20 | Novartis Pharmaceuticals | Results New Novartis data shows Cosentyx(TM) is significantly superior to Stelara® and clears skin (PASI 90) in nearly 80% of psoriasis patients novartis.com ↗
Novartis announced today results from the CLEAR study demonstrating that Cosentyx(TM) (secukinumab) is significantly superior to Stelara ® * (ustekinumab), a widely used biologic, in achieving clear or almost clear skin for psoriasis patients[1]. |
| 2015-03-13 | Novartis Pharmaceuticals | Results Novartis to present new late-breaking CosentyxTM data at AAD 2015 showing significant patient benefit in achieving clear skin novartis.com ↗
New data from the CLEAR study will include results that demonstrate Cosentyx is superior to Stelara ® * (ustekinumab) in clearing skin (PASI 90 and PASI 100) at Week 16[1]. |
| 2015-01-21 | Novartis Pharmaceuticals | Regulatory Novartis announces FDA approval for first IL-17A antagonist Cosentyx(TM) (secukinumab) for moderate-to-severe plaque psoriasis patients novartis.com ↗ |
| 2015-01-19 | Novartis Pharmaceuticals | Regulatory Novartis Cosentyx(TM) is the first IL-17 inhibitor to receive EU approval for first-line treatment of moderate-to-severe psoriasis patients novartis.com ↗
Novartis announced today that the European Commission (EC) has approved Cosentyx(TM) (secukinumab, formerly known as AIN457) as a first-line systemic* treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy. |
All press releases naming this drug 100 releases
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 206 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Secukinumab | “A 16-week Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study to Evaluate the Efficacy, Safety and Tolerability of Subcutaneous...” NCT00928512 ↗161“To determine the efficacy and safety of different doses of secukinumab, a fully human monoclonal antibody for targeted interleukin-17A blockade, in patients with noninfectious uveitis.” PMID 23290985 ↗ Jan 2013 “This withdrawn study was to assess the safety and efficacy of secukinumab compared to etanercept and placebo in patients who have moderate to severe, chronic, plaque-type psoriasis.” NCT01900782 ↗ “This study will characterize the pharmacokinetic, safety and immunogenicity of BR201 versus Cosentyx（Secukinumab ） in healthy male subjects after a single dose.” NCT06126718 ↗ “The authors tested whether the anti-interleukin (IL)-17A monoclonal antibody secukinumab was safe and effective for the treatment of active Crohn's disease.” PMID 22595313 ↗ May 2012 “CT-P55, containing the active ingredient secukinumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Cosentyx.” NCT07054970 ↗ “Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple Sclerosis” NCT01874340 ↗ “Secukinumab (Cosentyx)” NCT07149792 ↗ |
| Known as | AIN457 | “This is a post-approval commitment study to evaluate efficacy, and safety of two dosing regimens of secukinumab (AIN457), 300 mg every four weeks (Q4W) and every two weeks...” NCT07489573 ↗50“Efficacy at 24 Weeks and Long Term Safety, Tolerability and Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Psoriatic Arthritis (PsA)” NCT01392326 ↗ “Secukinumab (AIN457) 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose).” NCT01952015 ↗ “Open-label Secukinumab PFS (prefilled syringe) will be labeled as AIN457 150mg/1mL” NCT05622708 ↗ “with Secukinumab (AIN457) as a First-line Biologic” NCT03906136 ↗ “secukinumab (AIN457) 150mg or 300mg subcutaneous” NCT01358578 ↗ “secukinumab (AIN457) 150mg or 300mg subcutaneous” NCT01365455 ↗ “AIN 457 core study /AIN 457 Extension” NCT01433250 ↗ “Secukinumab (AIN457) 150 mg s.c.” NCT01989468 ↗ “Secukinumab (AIN457) 150 mg s.c.” NCT02763046 ↗ “Drug: Secukinumab (AIN457)” NCT02547714 ↗ |
| Known as | AIN457A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01169844 ↗ |
| Known as | CMAB015 | “new process CMAB015（Secukinumab ） 150 mg Subcutaneous injection in upper arm” NCT07254325 ↗ |
| Known as | Cosentyx | “CT-P55, containing the active ingredient secukinumab, is being developed by CELLTRION, Inc. as a proposed biosimilar to the reference product, Cosentyx.” NCT07054970 ↗17“administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma” NCT07237594 ↗ “Combining Cosentyx (Secukinumab) (4-weekly, 300 mg s.c.) With a Lifestyle Intervention to Cosentyx Therapy Alone” NCT03440736 ↗ “About 20 patients suffering from severe psoriasis will take Cosentyx vials by intravenous infusion as :” NCT06729463 ↗ “the reference product secukinumab (Cosentyx®) in healthy Chinese male subjects” PMID 39224901 ↗ Aug 2024 “Cosentyx（Secukinumab ） 150 mg Subcutaneous injection in upper arm” NCT07254325 ↗ “Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX]” NCT04403243 ↗ “Secukinumab Auto-Injector [Cosentyx]” NCT04414605 ↗ “Secukinumab 150 milligram [Cosentyx]” NCT03639740 ↗ “Secukinumab (Cosentyx)” NCT07149792 ↗ |
| Known as | Cosentyx TM | “"Secukinumab" "Cosentyx TM" 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.” NCT02795416 ↗ |
| Known as | Secukinumab (AIN457) 150 mg s.c. | “Secukinumab (AIN457) 150 mg s.c.” NCT02159053 ↗ |
| Action | Inhibit | “Anti IL-17 Monoclonal Antibody” NCT00584740 ↗ |
| Modality | Monoclonal antibody | “Anti IL-17 Monoclonal Antibody” NCT00584740 ↗ |
| Route | Intravenous | “AIN457 10 mg/kg was given as an intravenous infusion at day 1 and day 22.” NCT00584740 ↗ |
| Target | IL17A | “a human antibody to IL-17A” PMID 20926833 ↗ Oct 2010 |